The impact of PLCO control arm contamination on perceived PSA screening efficacy (Q36567476)

15 August 2017

The impact of PLCO control arm contamination on perceived PSA screening efficacy (English)

1 reference

15 August 2017

4

Angela B Mariotto

1 reference

15 August 2017

Roman Gulati

1

1 reference

15 August 2017

Alex Tsodikov

2

1 reference

15 August 2017

Elisabeth M Wever

3

1 reference

15 August 2017

Eveline A M Heijnsdijk

5

1 reference

15 August 2017

Jeffrey Katcher

6

1 reference

15 August 2017

Harry J de Koning

7

1 reference

15 August 2017

Ruth Etzioni

8

1 reference

15 August 2017

10 April 2012

1 reference

15 August 2017

Cancer Causes & Control

1 reference

15 August 2017

23

1 reference

15 August 2017

6

1 reference

15 August 2017

827-835

1 reference

describes a project that uses

15 August 2017

1 reference

10 June 2022

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pmc&rettype=xml&id=3556907

cites work

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Screening for prostate cancer with PSA testing: current status and future directions.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

What can be concluded from the ERSPC and PLCO trial data?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Calibrating disease progression models using population data: a critical precursor to policy development in cancer control

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Stage-specific cancer incidence: an artificially mixed multinomial logit model

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Screening and prostate-cancer mortality in a randomized European study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Mortality results from a randomized prostate-cancer screening trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

The prostate cancer prevention trial: design, biases and interpretation of study results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

ERSPC and PLCO prostate cancer screening studies: what are the differences?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Radical prostatectomy versus watchful waiting in early prostate cancer

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556907

Evidence of a Healthy Volunteer Effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

21 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10552-012-9951-8

Adjusting for non-compliance and contamination in randomized clinical trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22488488

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A population model of prostate cancer incidence

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22488488

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10552-012-9951-8

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

22488488

1 reference